Tests a new follow-up method for people with early-stage melanoma
Tests a new self-check follow-up method in adults with early melanoma.
Plain-language title generated from the registry record
Registry title: The MELAcare Study: A New Method for Surveillance of Melanoma Patients
Key facts
- Where
- Copenhagen, DenmarkSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who recently had surgery for early-stage melanoma (stages IA-IIA). It tests a new way of follow-up care, where patients check their own skin with support from clinicians.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- Clinical stage IA-IIA melanoma, treated with surgery within 3 months before joining.
- Earlier treatment
- Must have had surgery for the melanoma within 3 months before joining. No earlier melanoma before this diagnosis.
Main reasons for not taking part
- Advanced melanoma (stages IIB, IIC, III or IV)
- High risk of a new melanoma (dysplastic nevus syndrome or family history of melanoma)
- Earlier melanoma before this diagnosis
- Earlier cancer, except non-melanoma skin cancer
- Illness or disability that makes skin self-examination impossible
Read by machine on 9 November 2026.
Where in Denmark
- Herlev and Gentofte HospitalCopenhagen, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Herlev and Gentofte Hospital
- Trial code
- NCT05253872
- Record updated
- 26 June 2023
- Original description
The aim of this study is to evaluate a new method of follow-up for patients with low and intermediate risk (stages IA-IIA) melanoma. The investigators will compare different tools for patient support and education combined with clinician supported skin self-examination (SSE) to the current standard-of-care. The hypothesis is that meta-cognitive strategies and clinician supported SSE can lower fear of cancer recurrence (FCR) and promote effective SSE on a regular basis without compromising the detection of new primary melanomas and/or metastases.Read full original descriptionShow less
The MELAcare Study: a Randomized Controlled Trial of a New Method for Surveillance of Melanoma Patients
The aim of this study is to evaluate a new method of follow-up for patients with low and intermediate risk (stages IA-IIA) melanoma. The investigators will compare different tools for patient support and education combined with clinician supported skin self-examination (SSE) to the current standard-of-care. The hypothesis is that meta-cognitive strategies and clinician supported SSE can lower fear of cancer recurrence (FCR) and promote effective SSE on a regular basis without compromising the detection of new primary melanomas and/or metastases.
Inclusion: Ability to read and understand Danish language; Willing and able to give written informed consent; Surgical treatment of a clinical stage IA-IIA melanoma within 3 months of inclusion.
Exclusion: History of melanoma skin cancer prior to the index diagnosis; Patients with high risk of a new primary melanoma (dysplastic nevus syndrome, or family history of melanoma); Previous cancer, excluding non-melanoma skin cancer; Comorbidity that makes skin self-examination impossible (e.g. physical or mental disabilities, dementia or decreased cognitive function); Advanced melanoma, clinical stages IIB, IIC, III, or IV; non-detection of sentinel node in IB and IIA patients.